[
1. Aktas M., Auguste D., Lefebvre H.P., Toutain P.L., Braun J.P.: Creatine kinase in the dog: a review. Vet Res Commun 1993, 17, 353-369.10.1007/BF01839386
]Search in Google Scholar
[
2. Aktas M., Auguste D., Concordet D., Vinclair P., Lefebvre H., Toutain P.L., Braun J.P.: Creatine kinase in dog plasma: preanalytical factors of variation, reference values and diagnostic significance. Res Vet Sci 1994, 56, 30-36.10.1016/0034-5288(94)90192-9
]Search in Google Scholar
[
3. Aktas M., Lefebvre H.P., Toutain P.L., Braun J.P.: Disposition of creatine kinase activity in dog plasma following intravenous and intramuscular injection of skeletal muscle homogenates. J Vet Pharmacol Ther 1995, 18, 1-6.10.1111/j.1365-2885.1995.tb00542.x7752299
]Search in Google Scholar
[
4. Amelink G.J., Kamp H.H., Bar P.R.: Creatine kinase isoenzyme profiles after exercise in the rat: sex-linked differences in leakage of CK-MM. Pflugers Arch 1988, 412, 417-421.10.1007/BF019075613174399
]Search in Google Scholar
[
5. Åstrand J., Aspenberg P.: Reduction of instability-induced bone resorption using bisphosphonates. High doses are needed in rats. Acta Orthop Scand 2002, 73, 24-30.10.1080/00016470231728136911928907
]Search in Google Scholar
[
6. Barbier A., Breliere J.C., Remandet B., Roncucci R.: Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann Rheum Dis 1986, 45, 67-74.10.1136/ard.45.1.6710018173754110
]Search in Google Scholar
[
7. Benfold H.L., Frich J.C., Auriola S., Monkkonen J., Rogers M.J.: Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999, 56, 131-140.10.1124/mol.56.1.13110385693
]Search in Google Scholar
[
8. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C., Man Z., Mautalen C., Mesenbrink P., Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T.F., Sellmeyer D., Eriksen E.F., Cummings S.R.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356, 1809-1822.10.1056/NEJMoa06731217476007
]Search in Google Scholar
[
9. Calsey J.D., King D.J.: Clinical chemical values for some common laboratory animals. Clin Chem 1980, 26, 1877-1879.10.1093/clinchem/26.13.1877
]Search in Google Scholar
[
10. Drake M.T., Clarke B.L., Khosla S.: Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc, 2008, 83, 1032-1045.10.4065/83.9.1032266790118775204
]Search in Google Scholar
[
11. Dufour D.R., Lott J.A., Nolte F.S., Gretch D.R., Kaff R.S., Seeff L.B.: Diagnosis and monitoring of hepatic injurv. I. Performance characteristics of laboratory tests. Clin Chem 2000, 46, 2027-2049.10.1093/clinchem/46.12.2027
]Search in Google Scholar
[
12. Fleisch H.: Bisphosphonates: mechanisms of action. Endocr Rev 1998, 19, 80-100.10.1210/edrv.19.1.03259494781
]Search in Google Scholar
[
13. Francis M.D., Hovancik K., Boyce R.W.: A diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React 1989, 11, 239-252.
]Search in Google Scholar
[
14. Frith J.C., Monkkonen J., Blackburn G.M., Russell R.G., Rogers M.J.: Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5’-(beta, gammadichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997, 12, 1358-1367.10.1359/jbmr.1997.12.9.13589286751
]Search in Google Scholar
[
15. Geoffroy V., Paschalis E.P., Libouban H., Blouin S., Ostertag A., Chappard D., Cros M., Phipps R., de Vernejoul M.C.: Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures. Calcif Tissue Int 2011, 88, 464-475.10.1007/s00223-011-9480-621455736
]Search in Google Scholar
[
16. Goodship A.E., Blunn G.W., Green J., Coathup M.J.: Prevention of strain-related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate. J Orthop Res 2008, 26, 693-703.10.1002/jor.2053318050308
]Search in Google Scholar
[
17. Laterza O.F., Lim L., Garret-Engele P.W., Vlasakova K., Muniappa N., Tanaka W.K., Johnson J.M., Sina J.F., Fare T.L., Sistare F.D., Giaab E.: Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 1983, 55, 1977-1983.10.1373/clinchem.2009.13179719745058
]Search in Google Scholar
[
18. Lewis G., Janna S.: Aldendronate in bone cement. Clin Orthop Rel Res 2006, 445, 233-238.10.1097/01.blo.0000201162.59819.2816446596
]Search in Google Scholar
[
19. Maksymowych W.P.: Bisphosphonates - Anti-inflammatory properties. Curr Med Chem - Anti-Inflammatory & Anti-Allergy Agents 2002, 1, 15-28.10.2174/1568014024606539
]Search in Google Scholar
[
20. Matuszewski Ł., Matuszewska A., Jaszek M., Grąz M., Mazurkiewicz T., Gągała J., Polkowska I.: Determination of pamidronate in bisphosphonate-enriched cement implanted in rats by ion-pair HPLC and capillary electrophoresis. Bull Vet Inst Pulawy 2013, 57, 257-262.10.2478/bvip-2013-0045
]Search in Google Scholar
[
21. Matuszewski Ł., Turżańska K., Matuszewska A., Jabłoński M., Polkowska I., Mazurkiewicz T.: Effect of implanted bisphosphonate-enriched cement on the trabecular microarchitecture of bone in a rat model using micro-computed tomography. Int Orthop 2013, 37, 1187-1193.10.1007/s00264-013-1855-z366416923503639
]Search in Google Scholar
[
22. Matuszewski Ł., Olchowik G., Mazurkiewicz T., Kowalczyk B., Zdrojewska A., Matuszewska A., Ciszewski A., Gospodarek M., Morawik I.: Biomechanical parameters of the BP-enriched bone cement. Eur J Orthop Surg Traumatol 2013, DOI 10.1007/s00590-013-1230-I.10.1007/s00590-013-1230-1399085623670846
]Search in Google Scholar
[
23. Mazurkiewicz T., Matuszewski Ł., Matuszewska A., Jaszek M.: Implanted bisphosphonates in bone cement affect bone markers in rat serum. Int Orthop 2013, 37, 969-974.10.1007/s00264-013-1816-6363149823404413
]Search in Google Scholar
[
24. Moss D.W., Henderson A.R.: Enzymes. In: Fundamentals of Clinical Chemistry, Burtis C.A., Ashworth E.R., W.B. Saunders Company, Philadelphia 1996, pp. 283-335.
]Search in Google Scholar
[
25. Osterman T., Kippo K., Lauren L., Hannuniemi R., Sellman R.: Effect of clodronate on established adjuvant arthritis. Rheumatol Int 1994, 14, 139-147.10.1007/BF005796997871332
]Search in Google Scholar
[
26. Pennanen N., Lapinjoki S., Urti A., Monkkonen J.: Effect of liposomal and free bisphosphonates on the IL-1 β, IL-6 and TNF secretion from RAW 264 cells in vitro. Pharm Res 1995, 12, 916-922.10.1023/A:1016281608773
]Search in Google Scholar
[
27. Qi M., Hu J., Li J., Li J., Dong W., Feng X., Yu J.: Effect of zoledronate acid treatment on osteointegration and fixation of implants in autologous iliac bone grafts in ovariectomized rabbits. Bone 2012, 50, 119-27.10.1016/j.bone.2011.10.01122023930
]Search in Google Scholar
[
28. Schindeler A., Birke O., Yu N.Y., Morse A., Ruys A., Baldock P.A., Little D.G.: Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate. J Bone Joint Surg Br 2011, 93, 1134-1139.10.1302/0301-620X.93B8.2594021768643
]Search in Google Scholar
[
29. Schlattner U., Schlattner-Tokaska M., Wallimann T.: Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta 2006, 1762, 164-180.10.1016/j.bbadis.2005.09.00416236486
]Search in Google Scholar
[
30. Viereck V., Emons G., Lauck V., Frosch K-H., Blaschke S., Grundker C., Hofbauer L.: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002, 291, 680-686.10.1006/bbrc.2002.651011855844
]Search in Google Scholar
